Generated by AI
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing. Its portfolio centers on immuno-oncology and immuno-regulatory applications, with product candidates aimed at treating solid tumors, blood cancers, and autoimmune disorders. Fate Therapeutics also applies its cell programming approach to engineer synthetic controls of cell function and produce renewable master cell lines for scalable development. Headquartered in San Diego, California, Fate Therapeutics plays a specialized role in the advanced cell therapy market, where it supports the transition from donor-derived treatments to more standardized, engineered therapeutic products.
Website12278 Scripps Summit Drive
San Diego, CA, 92131
United States
The latest articles about FATE.
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria Encouraging safety profile with no dose-limiting toxicities, high-grade CRS, ICANS, GvHD or IEC-HS in autoimmune patients treated with a single dose of FT819; low incidences of infection and cytopenia were also observed Clinical data reinforces the patie
Summary of Nov 16's posts. Generated by AI.
Summary of May 5's posts. Generated by AI.
Summary of Jan 6's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about FATE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.